Richard A Anderson 1, David Cameron 2, Florian Clatot 3, Isabelle Demeestere 4, Matteo Lambertini 5 6, Scott M Nelson 7 8 9, Fedro Peccatori 10 Abstract Background: Female patients undergoing anticancer treatment are at elevated risk of adverse ovarian outcomes including infertility and premature ovarian insufficiency (POI), which is associated with short- and long-term health risks. Anti-Müllerian hormone (AMH) is a key biomarker of ovarian reserve, but its role prior to … Continue reading Anti-Müllerian Hormone as a Marker of Ovarian Reserve and Premature Ovarian Insufficiency in Children and Women With Cancer: A Systematic Review